NDAORAL-28TABLET
Approved
Apr 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
MIRCETTE (desogestrel; ethinyl estradiol) by Teva is clinical pharmacology pharmacodynamics combined oral contraceptives act by suppression of gonadotropins. Approved for pregnancy in women. First approved in 1998.
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIRCETTE is a combined oral contraceptive tablet containing desogestrel (progestin) and ethinyl estradiol (estrogen). It prevents pregnancy through suppression of gonadotropins and ovulation, while also altering cervical mucus and endometrium to reduce implantation likelihood. The active metabolite 3-keto-desogestrel exhibits high progestational activity with minimal androgenicity.
$0.006BPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal Part D spending and few claims; brand team likely focused on retention and generic transition planning rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Combined oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus, which increase the difficulty of sperm entry into the uterus,…
Worked on MIRCETTE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.